The maximum inhibition in the CML content was recorded as 38.7% and 33.77% with the treatment of PFT-HSA-TFT-Cy7 and PFT-Hcy-HSA-Cy7 as compared to their respective control (Figure 5(c)). The gene discussed is TBXT; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.